Adenovirus-mediated inhibitor κB gene transfer improves the chemosensitivity to anticancer drugs in human lung cancer in vitro and in vivo

Anticancer Research

Volumn 28, Issue 2 A, 2008, Pages 601-608

  Ni, Jian ^a,b   Takayama, Koichi ^a   Ushijima, Rie ^a   Inoshima, Naoko ^a   Uchino, Junji ^a   Harada, Taishi ^a   Minami, Takahiro ^a   Takeshita, Masafumi ^a   Zhou, Caicun ^b   Nakanishi, Yoichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b SHANGHAI PULMONARY HOSPITAL   (China)

Author keywords

Apoptosis; Chemosensitivity; I B ; NF B

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CASPASE 3; ETOPOSIDE; IFOSFAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; PACLITAXEL; PROTEIN P53; VASCULOTROPIN;

ADENOVIRUS; APOPTOSIS; ARTICLE; CELL GROWTH; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE TRANSFER; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; GENE TRANSFER TECHNIQUES; GENES, P53; HUMANS; I-KAPPA B PROTEINS; LUNG NEOPLASMS; MICE; NF-KAPPA B; PACLITAXEL; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 42549111637     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Wang CY, Cusack JC Jr, Liu R and Baldwin AS Jr: Control of inducible chemoresistance: Enhanced antitumor therapy through increased apoptosis by inhibition of NFκB. Nat Med 5: 412-417, 1999.
2. Kasibhatla S and Tseng B: Why target apoptosis in cancer treatment? Mol Cancer Ther 2: 573-580, 2003.
3. Friedlander RM: Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 348: 1365-1375, 2003.
4. Chen F, Gastranova V and Shi XL: New insights into the role of nuclear factor kappaB in cell growth regulation. Am J Pathol 59: 387-397, 2001.
5. Pei XH, Nakanishi Y, Takayama K, Bai F and Hara N: Benzo[a]pyrene activates the human p53 gene through induction of nuclear factor κB activity. J Biol Chem 274: 35240-35246, 1999.
6. Sánchez-Pérez I, Benitah SA, Martínez-Gomariz M, Lacal JC and Perona R: Cell stress and MEKK1-mediated c-Jun activation modulate NFκB activity and cell viability. Mol Biol Cell 13: 2933-2945, 2002.
7. Huang Y, Johnson KR, Norris JS and Fan W: Nuclear factor-κB/ IκB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res 60: 4426-4432, 2000.
8. Biswas DK, Martin KJ, McAlister C, Cruz AP, Graner E, Dai SC and Pardee AB: Apoptosis caused by chemotherapeutic inhibition of nuclear factor-κB activation. Cancer Res 63: 290-295, 2003.
9. Kaltschmidt B, Kaltschmidt C, Hofmann TG, Hehner SP, Droge W and Schmitz ML: The pro- or anti-apoptotic function of NF-κB is determined by the nature of the apoptotic stimulus. Eur J Biochem 267: 3828-3835, 2000.
10. Fujioka S, Sclabas GM, Schmidt C, Frederick WA, Dong QG, Abbruzzese JL, Evans DB, Baker C and Chiao PJ: Function of nuclear factor κB in pancreatic cancer metastasis. Clin Cancer Res 9: 346-354, 2003.
11. Ni J, Takayama K, Inoshima N, Uchino J, Harada A, Minami T, Harada T, Zhou C and Nakanishi Y: Gene transfer of inhibitor kappaB in human lung cancer cell line NCI-H460 inhibits tumorigenesis and angiogenesis in vivo. Anticancer Res 25: 69-77, 2005
12. Lavon I, Pikarsky E, Gutrovich E, Goldberg I, Bar J, Oren M and Ben-Neriah Y: Nuclear factor kappaB protects the liver against genotoxic stress and functions independently of P53. Caner Res 63: 25-30, 2003.
13. Kawasaki M, Nakanishi Y, Kuwano K, Takayama K, Kiyohara C and Hara N: Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer. Eur J Cancer 34: 1352-1357, 1998.
14. Inoshima N, Nakanishi Y, Minami T, Izumi M, Takayama K, Yoshino I and Hara N: The influence of dendritic cell infiltration and VEGF expression on the prognosis of NSCLC. Clin Cancer Res 8: 3480-3486, 2002.
15. Nishio M, Koshikawa T, Kuroishi T, Suyama M, Uchida K, Takagi Y, Washimi O, Sugiura T, Ariyoshi Y, Takahashi T, Ueda R and Takahashi T: Prognostic significance of abnormal p53 accumulation in primary, resected non-small cell lung cancer. J Clin Oncol 14: 497-502, 1996.
16. Mattern J, Koomagi R and Volm M: Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumor cell proliferation in human epidermoid lung carcinoma. Br J Cancer 73: 931-934, 1996.
17. Tergaonkar V, Pando M, Vafa O, Wahl G and Verma I: P53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell 1: 493-503, 2002
18. Galmarini CM: P-glycoprotein expression by cancer cells affects cell cytotoxicity and cell-cycle perturbations induced by six chemotherapeutic drugs. J Exp Ther Oncol 2: 146-152, 2002.
19. Schondorf T, Kurbacher CM, Gohring UJ, Benz C, Becker M, Sartorius J, Kolhagen H, Mallman P and Neumann R: Induction of MDR1-gene expression by antineoplastic agents in ovarian cancer cell lines. Anticancer Res 22: 2199-2203, 2002.
20. Yu D: Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers. Semin Oncol 28: 12-17, 2001.
21. Monzo M, Rosell R, Sanchez JJ, Lee JS, O'Brate A, Gonzalez-Larriba JL, Alberola V, Lorenzo JC, Nunez L, Ro JY and Martin C: Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 17: 1786-1793, 1999.
22. Kawakami Y, Hama S, Hiura M, Nogawa T, Chiba T, Yokoyama T, Takashima S, Tajiri H, Eguchi K, Nagai N, Shigemasa K, Ohama K, Kurisu K and Heike Y: Adenovirus-mediated p16 gene transfer changes the sensitivity to taxanes and Vinca alkaloids of human ovarian cancer cells. Anticancer Res 21: 2537-2545, 2001.
23. Cip/WAF1 and promotes cell survival. J Biol Chem 277: 11352-11361, 2002.
24. Laframboise S, Chapman W, McLaughlin J and Andrulis IL: p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance. Cancer J 6: 302-308, 2000.
25. Liu JR, Fletcher B, Page C, Hu C, Nunez G and Baker V: Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol Oncol 70: 398-403, 1998.
26. KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice. Cancer Res 61: 1280-1284, 2001.
27. Arlt A and Schafer H: NFkappaB and chemoresistance in solid tumors. Int J Clin Pharmacol Ther 40: 336-347, 2002.
28. Dobrzanski P, Ryseck RP and Bravo R: Differential interactions of Rel-NFκB complexes with IκBα determine pools of constitutive and inducible NFκB activity. EMBO J 13: 4608-4616, 1994.
29. MacFarlane M: TRAIL-induced signaling and apoptosis. Toxicol Lett 139: 89-97, 2003.
30. Baetu TM and Hiscott J: On the TRAIL to apoptosis. Cytokine Growth Factor Rev 13: 199-207, 2003.
31. Osaki S, Nakanishi Y, Takayama K, Pei XH, Ueno H and Hara N: Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells. Cancer Gene Ther 7: 300-307, 2000.
32. Chen F, Castranova V and Shi X: New insights into the role of nuclear factor-κB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 45: 7-17, 1999.
33. Collins TS, Lee LF and Ting JP: Paclitaxel up-regulates IL-8 synthesis in human lung carcinoma through an NFκB and AP-1 dependent mechanism. Cancer Immuno Immunother 49: 78-84, 2000.
34. Huang S, Pettaway CA, Uehara H, Bucana CD and Fidler IJ: Blockage of NFκB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20: 4188-4197, 2001.
35. Huang S, Robinson JB, Deguzman A, Bucana CD and Fidler IJ: Blockage of NFκB signaling inhibits the angiogenesis and tumorigenecity of human ovarian cancer cells by suppressing expression of VEGF and interleukin 8. Cancer Res 60: 5334-5339, 2000.
36. Rak J, Filmus J, Finkenzeller G, Grugei S, Marme D and Kerbel RS: Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 14: 263-277, 1995.